GH Research (NASDAQ:GHRS - Get Free Report) released its earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06, Zacks reports.
GH Research Stock Down 9.1 %
Shares of GHRS stock traded down $0.92 during trading on Monday, reaching $9.21. 610,686 shares of the company's stock were exchanged, compared to its average volume of 154,116. GH Research has a twelve month low of $6.00 and a twelve month high of $20.50. The firm's fifty day moving average price is $10.51 and its 200-day moving average price is $9.19. The stock has a market capitalization of $479.18 million, a PE ratio of -11.66 and a beta of 0.93.
Analysts Set New Price Targets
Several research analysts have weighed in on GHRS shares. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of GH Research in a research report on Monday, January 27th. Stifel Nicolaus boosted their target price on shares of GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday. Canaccord Genuity Group dropped their price target on shares of GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, November 18th. Finally, Cantor Fitzgerald assumed coverage on shares of GH Research in a research report on Thursday, February 13th. They issued an "overweight" rating and a $14.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $30.60.
Get Our Latest Research Report on GHRS
GH Research Company Profile
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Articles
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
